To evaluate feasibility and efficacy of haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation. To evaluate feasibility and efficacy of NK cell infusion after haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation.
HaploSCT following reduced-intensity conditioning (RIC) regimen will be performed in patients with high-risk solid tumors. Both parents will be evaluated for their KIR genotype and phenotype and the one with the greatest degree of KIR-L mismatch with the patient will be selected as the donor. In addition, ex-vivo expanded NK cells derived from the donor will then be administered after haploSCT to increase the GVT effect. Low-dose IL-2 will be given after expanded NK cell infusion to enhance NK cell alloreactivity.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Samsung Medical Center
Seoul, South Korea
Number of study patients with adverse events as a measure of safety of haploidentical stem cell transplantation and NK cell infusion
Time frame: within 30 days after transplantation
event-free survival and overall survival
efficacy of haploidentical stem cell transplantation and NK cell infusion in patients with high-risk solid tumors
Time frame: 3 years after transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.